Parkinson’s disease is on the rise, and scientists are scrambling to find new ways to ease its symptoms. A new study from the University of California San Francisco (UCSF) has highlighted psilocybin, a psychedelic compound found in certain mushrooms, as a potential source of relief. Known widely as “magic mushrooms,” this substance has shown promise in boosting mood, sharpening cognition, and improving motor symptoms in those with Parkinson’s.
The study stemmed from psilocybin’s known effects on depression and anxiety, conditions often found in Parkinson’s patients. These individuals frequently deal with intense mood issues that traditional antidepressants don’t adequately address, according to UCSF. Dr. Ellen Bradley, who led the study, pointed out, “Many people don’t realize this, but mood symptoms in Parkinson’s are linked to a faster physical decline.”
The study was small, involving only 12 participants aged between 40 and 75, all experiencing mild to moderate Parkinson’s. They also suffered from depression or anxiety. Participants were given a 10 mg dose of psilocybin followed by a 25 mg dose two weeks later, with their progress monitored by a licensed therapist.
Patients reported significant improvements in mood, cognition, and motor functions during follow-up sessions one week and one month later. “These results are really encouraging,” Dr. Bradley shared with Fox News Digital. Improvements in depression and anxiety were notable, lasting at least three months post-treatment.
Amir Inamdar, a pharmaceutical expert in the UK, found the motor symptom improvements particularly intriguing. He mentioned, “As the authors note, this could be because of the modulation of dopamine via psilocybin’s effect on several serotonin receptor types.” Despite some minor side effects like anxiety and headaches, the treatment was generally well-received.
While the study offers hope, it comes with limitations. It was the first of its kind to explore psychedelics in a neurodegenerative disease and had no control group, making definitive conclusions difficult. Dr. Bradley emphasized the need for larger, more rigorous trials to confirm these findings.
Currently, a larger trial is underway to explore psilocybin’s efficacy in Parkinson’s more thoroughly. Researchers are collecting detailed biological data to better understand how psilocybin works. This step is vital for refining psilocybin treatments and developing future psychedelics that might benefit Parkinson’s patients.
Dr. Bradley advises caution for those considering psilocybin, stating, “I wouldn’t recommend to my patients with Parkinson’s that they start using psilocybin.” She stresses the novelty of this research, highlighting that these drugs might not be safe for everyone with Parkinson’s.
Inamdar echoed these sentiments, noting the encouraging yet preliminary nature of the study. He remarked on the open-label design, which can lead to expectancy effects, but acknowledged that the mood and anxiety improvements were still evident after three months.
The research represents a promising step, but much work remains to identify how psilocybin can be optimally used for Parkinson’s treatment. The hope is to eventually find the right psychedelic therapy tailored to individual patient needs.
